Duration of immunotherapy in non-small cell lung cancer survivors: a lifelong commitment?
C Putzu, S Canova, P Paliogiannis, R Lobrano, L Sala… - Cancers, 2023 - mdpi.com
Simple Summary Lung cancer is one of the most common human cancers and the leading
cause of cancer-related mortality worldwide. The advent of immunotherapy for the treatment …
cause of cancer-related mortality worldwide. The advent of immunotherapy for the treatment …
Long‐term outcomes in patients with advanced and/or metastatic non–small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a …
H Kim, DW Kim, M Kim, Y Lee, HK Ahn, JH Cho… - Cancer, 2022 - Wiley Online Library
Background Immune checkpoint inhibitors (ICIs) have shown significant improvements in
patients with advanced non–small cell lung cancer (NSCLC). One of the major issues with …
patients with advanced non–small cell lung cancer (NSCLC). One of the major issues with …
Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a …
G Bilger, N Girard, H Doubre, MG Levra… - Cancer Immunology …, 2022 - Springer
Background The optimal treatment duration of ICIs for patients with advanced NSCLC
remains uncertain. In phase 3 clinical trials, treatment continued for 2 years or until disease …
remains uncertain. In phase 3 clinical trials, treatment continued for 2 years or until disease …
[HTML][HTML] Discontinuation of Immune checkpoint inhibitor due to irAEs in NSCLC patients with EGFR Mutation
S Okauchi, K Miyazaki, T Shiozawa… - Cancer Diagnosis & …, 2023 - ncbi.nlm.nih.gov
Background/Aim: Immune checkpoint inhibitors (ICIs) have revolutionized advanced non-
small cell lung cancer (NSCLC) treatment. Even patients with epidermal growth factor …
small cell lung cancer (NSCLC) treatment. Even patients with epidermal growth factor …
[HTML][HTML] Early discontinuation of immune checkpoint inhibitor therapy prior to disease progression in patients with metastatic non-small cell lung cancer: a survival …
BJ McKinley, TS Pai, EB Wolf, S Li… - Frontiers in …, 2024 - ncbi.nlm.nih.gov
Methods We conducted a retrospective observational study of all patients with mNSCLC
treated with ICIs, with or without combination chemotherapy, at 3 Mayo Clinic sites between …
treated with ICIs, with or without combination chemotherapy, at 3 Mayo Clinic sites between …
Programmed death‐ligand 1 expression and use of immune checkpoint inhibitors among patients with advanced non‐small‐cell lung cancer in a resource‐limited …
SH How, LM Tho, CK Liam, HH Hasbullah… - Thoracic …, 2022 - Wiley Online Library
Introduction Immune checkpoint inhibitor (ICI) therapy is an established treatment for
advanced non‐small‐cell lung cancer (NSCLC) and programmed death ligand‐1 (PD‐L1) …
advanced non‐small‐cell lung cancer (NSCLC) and programmed death ligand‐1 (PD‐L1) …
The right dose: from phase I to clinical practice
SL Groenland, MJ Ratain, LS Chen… - American Society of …, 2021 - ascopubs.org
To realize the full potential of promising new anticancer drugs, it is of paramount importance
to administer them at the right dose. The aim of this educational article is to provide several …
to administer them at the right dose. The aim of this educational article is to provide several …
Complete response of squamous cell carcinoma of the lung following treatment with pembrolizumab in an elderly patient: a case report
E Takeuchi, Y Okamoto, N Takahashi… - Thoracic …, 2021 - Wiley Online Library
Complete response of non–small cell lung cancer (NSCLC) with immune checkpoint
inhibitor (ICI) monotherapy is rare. Here, we encountered an elderly patient who showed …
inhibitor (ICI) monotherapy is rare. Here, we encountered an elderly patient who showed …
[HTML][HTML] Nivolumab plus carboplatin and paclitaxel as the first-line therapy for advanced squamous cell carcinoma of the lung with strong programmed death-ligand 1 …
FS Fan, CF Yang, CL Chang - Cureus, 2019 - ncbi.nlm.nih.gov
An 80-year-old male patient was diagnosed to have squamous cell carcinoma of the lung
which had a high level of programmed death-ligand 1 (PD-L1) expression. He was …
which had a high level of programmed death-ligand 1 (PD-L1) expression. He was …
Discontinuation of immune checkpoint inhibitor and survival in patients with non-small-cell lung cancer without a driver gene mutation
S Hattori, S Okauchi, Y Sasatani, G Ohara… - Anticancer …, 2022 - ar.iiarjournals.org
Background/Aim: Patients with non-small-cell lung cancer treated with immune checkpoint
inhibitors (ICI) might be forced to discontinue treatment for various reasons. We conducted a …
inhibitors (ICI) might be forced to discontinue treatment for various reasons. We conducted a …